Russell Schundler Sells 16,393 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the transaction, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Russell Schundler also recently made the following trade(s):

• On Monday, December 2nd, Russell Schundler sold 1,063 shares of Liquidia stock. The stock was sold at an average price of $11.51, for a total transaction of $12,235.13.

Liquidia Price Performance

Liquidia stock opened at $12.14 on Thursday. Liquidia Co. has a one year low of $8.26 and a one year high of $16.99. The business’s fifty day moving average is $11.23 and its 200 day moving average is $11.02. The stock has a market capitalization of $1.03 billion, a PE ratio of -7.45 and a beta of 0.23.

Institutional Trading of Liquidia

A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Liquidia by 18.2% during the second quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after purchasing an additional 32,076 shares during the last quarter. Rhumbline Advisers grew its position in Liquidia by 12.4% in the 2nd quarter. Rhumbline Advisers now owns 80,164 shares of the company’s stock worth $962,000 after purchasing an additional 8,871 shares during the period. Arizona State Retirement System raised its stake in Liquidia by 10.7% during the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after buying an additional 1,341 shares during the last quarter. Quest Partners LLC bought a new position in shares of Liquidia during the 2nd quarter valued at $27,000. Finally, Profund Advisors LLC boosted its stake in shares of Liquidia by 31.6% in the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after buying an additional 3,466 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LQDA shares. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, Scotiabank started coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Liquidia presently has a consensus rating of “Buy” and a consensus price target of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).